Overview

Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)

Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse. This study will assess the ability of the Power Doppler Ultrasonography (PDUS) to be a reliable marker of enthesitis response and relapse in subjects treated with infliximab.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Centocor, Inc.
Treatments:
Infliximab